市场调查报告书
商品编码
1468582
按类型(第一期和第二期梅毒、潜伏和三期梅毒)、检测地点(实验室检测、护理点 (POC) 检测)和地区分類的梅毒检测市场 2024-2032Syphilis Testing Market by Type (Primary and Secondary Syphilis, Latent and Tertiary Syphilis), Location of Testing (Laboratory Testing, Point-of-Care (POC) Testing), and Region 2024-2032 |
IMARC Group年,全球梅毒检测市场规模达12亿美元。性传染病(STD)的日益普及、流产发生率的增加以及医疗保健领域对有效疾病诊断和测试解决方案的需求不断增加是推动市场发展的一些关键因素。
梅毒是指一种性传染感染(STI),通常由性接触引起,并透过皮肤或黏膜接触在个体之间传播。它开始时是生殖器和口腔直肠上的无痛溃疡。如果不及时治疗,可能会引发第三期梅毒的併发症,这种疾病可能会损害大脑、神经、血管和关节。目前,快速血浆反应素(RPR)和性病研究实验室(VDRL)是从业人员正在使用的标准检测方法。这些方法提供早期检测,以便更好地治疗,并减轻性传染病 (STD) 的传播和发展。因此,实验室和护理点 (PoC) 中心经常使用梅毒检测来诊断梅毒类型并确定其适当的治疗方法。
对性病治疗的认识不断提高是推动市场成长的关键因素之一。据此,各国政府以及不同的非政府组织(NGO)正积极进行宣传活动,提高民众对预防性病(包括梅毒)和可用治疗方案的认识。这反过来又促进了梅毒快速检测试纸等梅毒检测试剂盒的采用,从而有利地支持了市场成长。这些试剂盒提供家庭测试和有效的诊断结果,以便及时做出决策,这也有助于市场的成长。此外,这些测试套件使用方便,并且可以在网上零售店和店内药房以实惠的价格轻鬆获得,这也促进了市场的成长。除此之外,医疗保健领域的显着改善以及最近推出有效治疗替代方案的研发(R&D)活动正在对市场成长产生积极影响。此外,针对性传播感染检测的优惠医疗报销政策的存在也促进了市场的成长。其他因素,例如包括梅毒在内的性病患病率不断上升、无保护性交发生率上升、有效筛检计画的广泛实施以及对疾病早期诊断的重视,正在为市场创造积极的前景。
The global syphilis testing market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032. The growing prevalence of sexually transmitted diseases (STDs), the increasing incidences of miscarriages, and the rising need for effective disease diagnosing and testing solutions in the healthcare sector represent some of the key factors driving the market.
Syphilis refers to a sexually transmitted infection (STI) that is usually caused by sexual contact and is spread amongst individuals through the skin or mucous membrane contact. It starts as a painless sore on the genitals and rectum of the mouth. If left untreated, it might trigger complications of tertiary syphilis, wherein the disease may damage the brain, nerves, blood vessels, and joints. At present, rapid plasma reagin (RPR) and venereal diseases research laboratory (VDRL) are standard testing practices that are being used by practitioners. These approaches provide early detection for better treatment and mitigate the spread and development of sexually transmitted diseases (STDs). As a result, syphilis testing is frequently used in laboratories and point-of-care (PoC) centers to diagnose the syphilis type and identify its proper treatment.
The increasing awareness regarding STD treatment represents one of the key factors driving the market growth. In line with this, governments of various nations, along with different non-governmental organizations (NGOs) are actively undertaking campaigns to sensitize the common mass regarding the prevention of STDs, including syphilis, and the available treatment options. This, in turn, is facilitating the adoption of syphilis testing kits, such as syphilis rapid test strips, which is favorably supporting the market growth. These kits offer at-home testing with effective diagnostic results, and thus timely decision-making, which is also contributing to the market growth. Additionally, the convenience of usage and the easy availability of these test kits at online retail stores and in-store pharmacies at affordable price points are contributing to the market growth. Apart from this, the considerable improvements in the healthcare sector and the recent research and development (R&D) activities to launch effective treatment alternatives are positively impacting the market growth. Moreover, the presence of favorable medical reimbursement policies for the testing of sexually transmitted infections is contributing to the market growth. Other factors, such as the increasing prevalence of STDs, including syphilis, rising incidences of unprotected sexual intercourse, the widespread implementation of effective screening programs, and an enhanced focus on the early diagnostic of the disease, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global syphilis testing market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type and location of testing.
Primary and Secondary Syphilis
Latent and Tertiary Syphilis
The report has also provided a detailed breakup and analysis of the syphilis testing market based on the type. This includes primary and secondary, and latent and tertiary syphilis. According to the report, primary and secondary syphilis represented the largest segment.
Laboratory Testing
Point-of-Care (POC) Testing
A detailed breakup and analysis of the syphilis testing market based on the location of testing has also been provided in the report. This includes laboratory and point-of-are (POC) testing. According to the report, laboratory testing accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for syphilis testing. Some of the factors driving the North America syphilis testing market included the increasing prevalence of STDs, significant technological advancements, and extensive research and development (R&D) activities.
The report has also provided a comprehensive analysis of the competitive landscape in the global syphilis testing market. Detailed profiles of all major companies have also been provided. Some of the companies covered includes Abbott Laboratories, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, DRG International Inc. (BioCheck Inc.), F. Hoffmann-La Roche AG, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.